ClinicalTrials.gg
RecruitingNCT06776783Updated Oct 13, 2026

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

A Phase 3 interventional study of APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system) and Control in Respiratory Distress Syndrome and Pre-term Infants, sponsored by Aerogen Pharma Limited. Recruiting at 31 sites in 3 countries. Open to participants aged 1 Hour to 24 Hours. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Aerogen Pharma Limited · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 13, 2026First sites in Canada and United Kingdom20 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
1 Hour to 24 Hours
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.

Planned enrollment
27th of 250
520 · median 52
Started
2025
with 13 others
Phase 3
36 of 324
5 open now
Primary completion
2027-05
later than 21 of 55 live
Registered
304th of 324
by date

Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 27th largest by planned enrollment of the 250 interventional ones that give a count, is one of 14 that started in 2025, is one of 36 in phase 3, reaches primary completion later than 21 of the 55 other live ones, and was the 304th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 1 Hour to 24 Hours · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Respiratory Distress Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham). In Part 1, subjects will be followed until they reach 40 weeks post-menstrual age (PMA) or are discharged from the NICU, whichever comes first. In Part 2, subjects will undergo post-term follow-up through 24 months corrected age.

03

Conditions studied

  • Respiratory Distress Syndrome
  • Pre-term Infants

Keywords

  • respiratory distress syndrome
  • surfactant
  • pre-term infant
04

Who can participate

Ages eligible
1 Hour to 24 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Inborn at the study site's hospital (i.e., not transferred from another hospital following delivery)
  2. Gestational age at birth of 26 through 33 weeks PMA
  3. Birth weight appropriate for gestational age (AGA, weight 3rd to 97th percentile on Fenton Growth Curve)
  4. Birth weight ≤ 2000 grams
  5. Post-natal age 1 to 24 hours at randomization
  6. On nCPAP or NIV for at least 30 minutes with RSS = 1.4 - 2.0 to maintain SpO2 90-95% at randomization. RSS is calculated as (nCPAP cm H2O) × (FiO2) or as (NIV mean airway pressure cm H2O) × (FiO2).
  7. FiO2 ≥ 0.24 at randomization
  8. nCPAP or mPaw ≥ 6 cm H2O at randomization
  9. Chest radiograph (CXR) or lung ultrasound compatible with RDS prior to randomization

Exclusion criteria

Exclusion Criteria:

  1. On SiPAP®, RAM® cannula, or high flow nasal cannula (HFNC) (> 2 liters per minute [LPM]) at the time of randomization
  2. Prior instillation of surfactant
  3. Premature rupture of membranes (PROM) occurring > 14 days before birth
  4. Significant congenital/chromosomal anomaly (e.g., Pierre Robin syndrome, congenital heart disease, or trisomy)
  5. Pneumothorax
  6. Other etiologies of respiratory distress
  7. Enrollment in another interventional study with similar efficacy endpoints
  8. Apgar score at 5 min of 0-3
  9. Prior cardiopulmonary resuscitation (CPR) or epinephrine
  10. Base Deficit > 15 mEq/L on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. Note that arterial blood gas is not required prior to randomization.
  11. Partial pressure of carbon dioxide (PaCO2) > 65 mmHg on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization.
  12. Triplet or higher order multiple birth
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
520 participants (estimated)

Study arms

  • Sham comparator
    Control Group

    Other: Control

  • Experimental
    APC-0101 Group

    Combination Product: APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)

Interventions

  • Combination productAPC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)

    Subjects in the APC-0101 group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface and APC-0101 treatment will be started.

  • OtherControl

    Subjects in the Control group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface but an empty vial will be used instead of APC-0101.

06

What researchers measure

Primary outcomes

  1. Failure Criteria

    Number (%) of subjects who meet the predetermined criteria for failure of nCPAP/NIV

    Time frame: First 7 days of life

Secondary outcomes

  1. Instilled Bolus Surfactant

    The number (%) of subjects in each group who receive instilled bolus surfactant.

    Time frame: First 72 hours of life

  2. Multiple Bolus Surfactant Doses

    The number (%) of subjects in each group who receive multiple doses of bolus surfactant.

    Time frame: First 72 hours of life

  3. Total Number of Bolus Surfactant Doses

    The total number of bolus doses of surfactant received per subject in each group.

    Time frame: First 72 hours of life

07

Study locations

30 of 31 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for May 2027, 20 months after the start.

Of 39 phase 3 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 15, 2025
StartActual
Sep 24, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
20 sites added, 1 site removed — first sites in Canada and United Kingdom
Show 20 added (7 United States, 7 United Kingdom, 6 Canada)
  • University of California Davis Children's Hospital · Sacramento, United States
  • Sharp Mary Birch Hospital for Women & Newborns · San Diego, United States
  • University of Maryland Children's Hospital · Baltimore, United States
  • Tufts Medical Center · Boston, United States
  • Mount Sinai Hospital · New York, United States
  • University of Pittsburgh Medical Center Magee Women's Hospital · Pittsburgh, United States
  • University of Virginia Children's Hospital · Charlottesville, United States
  • Royal Alexandria Hospital · Edmonton, Canada
  • IWK Health Centre · Halifax, Canada
  • McMaster Children's Hospital · Hamilton, Canada
  • The Ottawa Hospital · Ottawa, Canada
  • Mount Sinai Hospital Toronto · Toronto, Canada
  • CHU de Québec-Université Laval · Québec, Canada
  • Royal Jubilee Maternity Hospital · Belfast, United Kingdom
  • The Royal London Hospital · London, United Kingdom
  • Whipps Cross University Hospital · London, United Kingdom
  • Newham University Hospital · London, United Kingdom
  • University College Hospital · London, United Kingdom
  • Royal Preston Hospital · Preston, United Kingdom
  • Princess Royal Hospital · Telford, United Kingdom
Show 1 removed
  • University of Virginia School of Medicine · Charlottesville, United States
Oct 13, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • University of Arkansas for Medical Sciences · Little Rock, United StatesContact •••0812→•••1028
  • Memorial Hospital of South Bend · South Bend, United StatesContact •••3048→•••7141
  • WVU Medicine Children's Hospital · Morgantown, United StatesContact m•••@hsc.wvu.edu · •••1202→m•••@hsc.wvu.edu · •••1202
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    20 sites added, 1 site removed — first sites in Canada and United Kingdom
    Show 20 added (7 United States, 7 United Kingdom, 6 Canada)
    • University of California Davis Children's Hospital · Sacramento, United States
    • Sharp Mary Birch Hospital for Women & Newborns · San Diego, United States
    • University of Maryland Children's Hospital · Baltimore, United States
    • Tufts Medical Center · Boston, United States
    • Mount Sinai Hospital · New York, United States
    • University of Pittsburgh Medical Center Magee Women's Hospital · Pittsburgh, United States
    • University of Virginia Children's Hospital · Charlottesville, United States
    • Royal Alexandria Hospital · Edmonton, Canada
    • IWK Health Centre · Halifax, Canada
    • McMaster Children's Hospital · Hamilton, Canada
    • The Ottawa Hospital · Ottawa, Canada
    • Mount Sinai Hospital Toronto · Toronto, Canada
    • CHU de Québec-Université Laval · Québec, Canada
    • Royal Jubilee Maternity Hospital · Belfast, United Kingdom
    • The Royal London Hospital · London, United Kingdom
    • Whipps Cross University Hospital · London, United Kingdom
    • Newham University Hospital · London, United Kingdom
    • University College Hospital · London, United Kingdom
    • Royal Preston Hospital · Preston, United Kingdom
    • Princess Royal Hospital · Telford, United Kingdom
    Show 1 removed
    • University of Virginia School of Medicine · Charlottesville, United States
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • University of Arkansas for Medical Sciences · Little Rock, United StatesContact •••0812→•••1028
    • Memorial Hospital of South Bend · South Bend, United StatesContact •••3048→•••7141
    • WVU Medicine Children's Hospital · Morgantown, United StatesContact m•••@hsc.wvu.edu · •••1202→m•••@hsc.wvu.edu · •••1202
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06776783
Lead sponsor
Aerogen Pharma Limited
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Sep 24, 2025
Primary completion
May 2027 (estimated)
Completion
May 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Medical Director
Contact
AF3inquiries@aerogenpharma.com
9196026411

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion